Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis with Focus on Safety

This retrospective analysis examined the use of JAK inhibitors, specifically tofacitinib and baricitinib, in treating severe alopecia areata (AA) within the Greek population. The study highlights that these treatments are effective and safe, particularly noting optimal tolerability in younger individuals. The findings support the use of JAK inhibitors as a viable option for managing severe forms of AA, contributing valuable real-world data to the existing body of research on these medications.